Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Continuous Furosemide in Cardiac Surgery Patients With Kidney Dysfunction
NCT04919564Phase 2Completed
- Sponsor
- National Cardiovascular Center Harapan Kita
- Start
- May 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute kidney injury (AKI) comparing Furosemide group with Placebo group (2 arms). Primary endpoints: Glomerular Filtration Rate at 120 hours, Therapeutic Dose of Continuous Diuretic Infusion at 28 days and 1 more. Started May 2021; status: completed.
02
Drugs
furosemide
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04919564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919564.